Wednesday , December 13 2017
Home / David L. Joffe, BSPharm, CDE, FACA (page 19)

David L. Joffe, BSPharm, CDE, FACA

David L. Joffe, BSPharm, CDE, FACA

(Editor-in-Chief Diabetes In Control) A graduate of University of Kentucky College of Pharmacy, he has practiced in the Tampa Bay area since 1986, has been providing diabetes and cardiovascular care in Tampa Bay since 1995, and spent 2 years as an Eckerd Patient Care Pharmacist managing over 100 diabetes patients. Dave currently sees patients in over 30 primary care and endocrinologists offices.

June 4, 2016

I was watching “Beyond the Tank” on TV last week. For those of you who are not familiar with that show, it is a followup to “Shark Tank” and looks at how businesses that the Sharks invested in are doing months later. This episode focused on Mission Belt company and …

Read More »

May 31, 2016

When you work with children with diabetes, you often find out that many times the parents blame themselves for causing the disease. After a time they move to overprotecting their children and keeping them from enjoying many of the fun things of life as they grow up. This constant banter …

Read More »

May 28, 2016

Back in December in my Editors Desk, I mentioned that a CDE/dietitian friend of mine enlightened me on the reasons that artificial sweeteners might have some effects on the gut flora of patients. Her solution was to start taking probiotics to correct the imbalance that was occurring. Over the years …

Read More »

May 23, 2016

In last week’s newsletter, we were discussing the melding of drugs and medical technology together to improve patient outcomes. This will be the wave of the future  as more Pharma companies enter into pay-for-performance contracts with insurers and better outcomes will be the only way they can be paid. This …

Read More »

May 21, 2016

This week, the FiercePharma website had a great article on pay-for-performance arrangements. Although these aren’t commonplace now, about 14% of U.S. payers have at least one pay-for-performance pricing arrangement, up from 10% in 2014, according to a new specialty reimbursement report from EMD Serono. Another 30% of plans say they’ll …

Read More »

Sometimes we are so interested in the process that we forget to look for the outcome with our patients. This means we take our diabetes patients and start low and go slow. This kind of treatment regimen may be following the “guidelines” but oftentimes getting to the goal we want …

Read More »

For many years we have known that amyloid deposits in the brain cause Alzheimer’s, and the more deposits the worse the disease becomes. In 2011 scientists from ModGene LLC and Scripps Research Institute found that these deposits in the brain may come from the liver. This week our clinical text …

Read More »

May 14, 2016

Over the past 4 months, we have had over 22 items looking at the cardiovascular effects of diabetes drugs. Some of the items were focused on the increased risk of cardiovascular events; others were focused on the benefits in patients to either prevent or help reduce cv events; and a third group …

Read More »

Patients have long told us that their grandmother lived to 100 and had diabetes for 40 years with no problems, or that no one in their family has had it before so how could they have gotten it? These patients usually become our worst nightmares because they don’t take their …

Read More »

May 7, 2016

According to Pulseanalytics, 46% of all employees have a $1000 or higher deductible, the majority of plans have 5 tiers of copays, and each year 20% more products require a prior authorization. This makes it harder and harder for our patients to get their medications, and according to Item 1 …

Read More »